Skip to main content

Lancet Launches EULAR 2017 and "A Platinum Age of Rheumatology"

The current Lancet edition for 10 June 2017 is a rheumatology rich collection.  

The editorial profiles this years European League Against Rheumatism (EULAR) Annual Congress, that will begin on Wednesday June 14, 2017.  This is a highlight year as EULAR celebrates its 70th anniversary.

EULAR President Dr. Gerd Burmester's opening message and meeting overview is highlighted on the EULAR Website. 

In the current issue, Drs. Ian McInness and Georg Schett review the underlying mechanisms that drive rheumatoid arthritis based on evolving data, trials and animal models.  Their overview of key cytokines, including tumour necrosis factor α, interleukin 6, and granulocyte–macrophage colony-stimulating factor and Janus kinase (JAK) inhibitors,  show how the great advances in RA treatment have come from bedside to bench (rather than the converse) in our understanding of rheumatoid disease.

Also in Lancet, Drs. Burmester and Janet Pope review the evolution of treatment strategies for rheumatoid arthritis. They review the therapeutic arsenal, the window of opportunity, rapid intervention, and treat-to-target assessment and medication adjustment to prevent or slow structural damage.

 Lastly, there are two landmark articles featured, including the seminal biosimilar NOR-SWITCH Study and the SPIRIT-P2 study of ixekizumab in psoriatic arthritis.An unprecedented range of therapeutic options for rheumatic diseases is now available—the new challenge is to make them accessible.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject